|
Heart failure
|
0.600 |
Biomarker
|
disease |
RGD |
[Effect of carvedilol and perindopril on Ca(2+) pump activity and Ca(2+)-release channel density in myocardial sarcoplasmic reticulum in rats with chronic heart failure following myocardial infarction].
|
19620082 |
2009 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Whether FGF23 is associated with increased HF risk in populations with hypertension and whether this association is weaker in the presence of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy is unknown.
|
30256890 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Whereas the results are not conclusive, there may be a significant interaction between ACE genotype and response to ACE inhibitors in patients with heart failure.
|
9869506 |
1998 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We studied 3365 hypertensive participants of the population-based Rotterdam Study, without heart failure at baseline for whom ACE-genotyping was successful.
|
15861031 |
2005 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We started medical treatment for heart failure with an angiotensin-converting-enzyme inhibitor, loop diuretic, and spironolactone.
|
29137066 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We report on the availability of cardiac diagnostic technologies and select medications for heart failure (β-blockers, ACE inhibitors and furosemide).
|
28490619 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We performed a meta-analysis of all case-control studies that evaluated the association between ACE I/D polymorphism and HF in humans.
|
22015653 |
2012 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We performed a cost-effectiveness analysis of treatment with patiromer, spironolactone, and an angiotensin-converting enzyme inhibitor (ACEI) in patients with New York Heart Association (NYHA) class III-IV HF compared with ACEI alone.
|
30194623 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We identified three cohorts of patients with heart failure (HF): sacubitril/valsartan patients with a prior HF diagnosis; patients with HF with reduced ejection fraction; and patients with HF treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker and a β-blocker.
|
30156128 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We identified 100 patients (15.9%) with omissions equalling 139 PPOs, and the most common PPOs were due to a lack of angiotensin-converting enzyme inhibitors in patients associated with heart failure or coronary heart disease (n = 23, 16.5%) and a lack of statins (n = 20; 14.4%) and aspirin (n = 20; 14.4%) in coronary heart disease.
|
31573715 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We genotyped 195 patients with heart failure and systolic left ventricular dysfunction (ejection fraction <40%) for angiotensin-converting enzyme insertion (I)/deletion (D) and chymase-1 (-1903G/A) polymorphisms.
|
18641516 |
2008 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found recently that in Ren-2 transgenic hypertensive rats (TGR) addition of soluble epoxide hydrolase inhibitor (sEHi) to treatment with angiotensin-converting enzyme inhibitor (ACEi), surprisingly, increased the mortality due to heart failure (HF) induced by creation of the aorto-caval fistula (ACF).
|
31177795 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We examined whether tolvaptan combined with an angiotensin II receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) is more effective than tolvaptan alone in the treatment of patients with heart failure (HF).
|
28484118 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated the long-term effects of RAS blockers (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker) on the clinical outcomes in patients with SCAD without heart failure (HF) who underwent percutaneous coronary intervention (PCI) with drug-eluting stent using a large-scale, multicenter, prospective cohort registry.
|
29489465 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We evaluated nuclear factor kappa B {NFkB, rs28362491 [-94ins/delATTG (W/D)]} and angiotensin converting enzyme {ACE; rs1799752 [Ins(I)/Del(D)]} gene polymorphisms and their correlation with thyroid function in patients with heart failure (HF).
|
23543433 |
2014 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We constructed class adherence indicators for angiotensin-converting enzyme (ACE)-inhibitors, beta-blockers, spironolactone, diuretics, and cardiac glycosides and GAIs (GAI3 adherence to first three classes of heart failure medication, GAI5 adherence to five classes).
|
15827061 |
2005 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We conducted a retrospective cohort study including consecutive adult patients followed at the HF clinic of a tertiary care center who had already been on an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB).
|
31665724 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We compared aspirin and warfarin for HF events (hospitalization, death, or both) in the 2,305 patients enrolled in the WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction) trial (98.6% on ACE inhibitor or ARB treatment), using conventional Cox models for time to first event (489 events).
|
28774396 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We assessed the relation between the ACE I/D polymorphism and the risk of incident heart failure in normotensive and hypertensive subjects.
|
15571830 |
2004 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We analyzed whether angiotensin-converting enzyme (ACE) mRNA expression in heart failure is altered in the atrial myocardium, and whether a correlation exists between atrial ACE mRNA expression and the parameters of left ventricular function.
|
10619441 |
1999 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We analyzed participants from PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in HF) with an available physical examination at baseline.
|
31510768 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Various medications used in the treatment of HF such as loop diuretics and angiotensin converting enzyme inhibitors have not demonstrated a reduction in sudden cardiac death (SCD); however, beta-blockers (BB) are effective in reducing mortality and SCD.
|
31598875 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia.
|
31179336 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using the 2008-2012 IBM MarketScan Commercial database, we followed 26,439 individuals aged 18-64 years with newly diagnosed HF and calculated their adherence (using the proportion of days covered (PDC) algorithm) to the five guideline-recommended medication categories: angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers; beta blockers; aldosterone receptor antagonists; hydralazine; and isosorbide dinitrate.
|
31545830 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Up-titration of angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and ivabradine was performed in our Heart Failure (HF) Unit.
|
29183646 |
2018 |